Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | TOP2A | P11388 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3721259 | 0.81 | HTT (0.35) | HTTALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL6618620 | 0.75 | CYP3A4 (0.44) | HTTALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL6622021 | 0.75 | GRM5 (0.33) | ALDH1A1KDM4ELMNA | |
| SCHEMBL8795590 | 0.75 | KDM4E (0.50) | HTTALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL14667001 | 0.72 | SMPD3 (0.36) | HPGDELANEALOX15TSHRLMNA | |
| SCHEMBL24548242 | 0.71 | HTT (0.38) | HTTALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL9935160 | 0.71 | HTT (0.38) | HTTALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL18878946 | 0.71 | HTT (0.38) | HTTALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL11837892 | 0.70 | SMPD3 (0.39) | HTTALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL6269053 | 0.70 | NR1I2 (0.40) | KDM4EHPGDHSD17B10NR1I2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023173083-A1 | TETRAHYDROINDOLE DERIVATIVES AS EGFR AND/OR HER2 INHIBTORS USEFUL FOR THE TREATMENT OF CANCER | SCORPION THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-8188083-B2 | Triazolopyridazines | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090270402-A1 | Novel triazolopyridazines | ABBVIE INC. | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270402-A1 | Novel triazolopyridazines | MAP3K5, MAP3K1, MAP3K2 | HTT 4687/4885ALDH1A1 435/4885KDM4E 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.